Ionis to host 2024 virtual Annual Meeting of Stockholders
The agenda for the event is as follows:
-
5:00 p.m. –
5:15 p.m. ET (2:00 p.m. –2:15 p.m. PT ) – Virtual Annual Meeting of Stockholders- All stockholders of record at the close of business on
April 8, 2024 , are invited to participate in the virtual Annual Meeting webcast, which will be broadcast live at http://www.virtualshareholdermeeting.com/IONS2024. - Stockholders of record will receive an official proxy card from their brokerage firm. Each proxy card contains a 16-digit control number required to log-in, vote and submit questions during the webcast.
- Ionis does not provide proxy cards or have access to proxy card information, including 16-digit control numbers. For help obtaining a proxy card or to locate their control number or for instructions to access the webcast, stockholders of record should contact their brokerage firm before
Thursday, May 23 . - A help line will be available on the registration page of the live webcast for participants requiring technical assistance in accessing or participating during the live event. There will not be a replay of this session.
- All stockholders of record at the close of business on
-
5:30 p.m. ET (2:30 p.m. PT ) – Virtual corporate update-
Brett P. Monia , Ph.D., Ionis' chief executive officer, will provide a general corporate update followed by a question-and-answer session. - All interested parties may access the webcast live at https://event.webcasts.com/starthere.jsp?ei=1659973&tp_key=9ca016319a. An archived replay of the webcast will be posted for a limited time following the meeting at that same address.
- Questions for management may be submitted in advance of the webcast and will be addressed during the question-and-answer portion of the webcast. Please submit questions via email to IonisAnnualMeeting@ionisph.com by
Tuesday, June 4 . Questions not addressed during the webcast will be answered by email following the meeting.
-
About
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionispharma.com and follow us on X (Twitter) and LinkedIn.
Ionis Pharmaceuticals Investor Contact:
Ionis Pharmaceuticals Media Contact:
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-host-2024-virtual-annual-meeting-of-stockholders-302145477.html
SOURCE